Statement from The California Commission on the Status of Women and Girls on Supreme Court Decision on FDA v. Alliance for Hippocratic Medicine

Today, the U.S. Supreme Court, in a unanimous decision, ruled in a way that ensures that mifepristone, an FDA-approved drug that is part of a two-step process approved for medication abortion, will remain accessible in states where it is legal. Mifepristone is an essential medication that has been safely and reliably in use for the last 23 years for a variety of purposes, including as an important option for people seeking to end a pregnancy.

The ruling does not change the fact that the fight for reproductive freedom remains ongoing.

“Today’s decision confirms that mifepristone will remain available, including on our state college and university campuses, despite national efforts to restrict the right to reproductive healthcare,” said Darcy Totten, Interim Executive Director of the California Commission on the Status of Women and Girls. “But those efforts to restrict the rights to medical privacy and self-determination continue, which is why the Commission will continue to remain steadfast in our commitment to supporting California’s leading efforts in protecting reproductive healthcare access.”

This ruling also protects California’s commitment to make mifepristone available to anyone seeking a medication abortion, as well as the current protocols under the College Student Right to Access Act, which provides for medication abortion access on all California’s public college and university campuses using private funding.